Health
New Radiotheranostic Agent Offers Targeted Therapy in Metastatic Kidney Cancer
Medical Xpress
Key Points
- The new 68Ga/177Lu-NYM096 agent both detects metastatic kidney cancer and provides targeted radiotherapy.
- The small molecule compound offers a safe strategy for late-stage patients by reducing common toxicity issues.
- The research was published in the September issue of The Journal of Nuclear Medicine.
Scientists have developed a new radiotheranostic pair called 68Ga/177Lu-NYM096. This agent can both detect tumors and deliver targeted radiotherapy in patients with metastatic clear cell renal cell carcinoma (ccRCC).
The method uses a small molecule compound to reduce toxicity issues commonly seen in existing treatments. This provides a safer and more feasible strategy for advanced-stage patients.
The research results were published in the September issue of The Journal of Nuclear Medicine.
React to this story
#Metastatic Kidney Cancer#Radiotheranostics#Nuclear Medicine#Targeted Radiotherapy#Clear Cell Renal Cell Carcinoma
Next storySugary drinks increase stomach cancer risk by 2.45 timesAsk about this story
Answers are AI-generated from this story only.
Frequently Asked Questions
- Which type of cancer was this new method developed for?
- It was developed for metastatic clear cell renal cell carcinoma (ccRCC).
- What is the main advantage of the radiotheranostic pair?
- It detects tumors while simultaneously applying targeted radiotherapy and reducing toxicity.
- In which journal was the research published?
- It was published in the September issue of The Journal of Nuclear Medicine.
This is an AI-generated summary. The full story lives at the source.
Read the full story at the sourcemedicalxpress.comHow we produce our content →Related stories
Health